Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system.

The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 ...

Insulet (Nasdaq:PODD) today hosted its Investor Day event, led by CEO Ashley McEvoy, laying out the future for the insulin ...

According to Precedence Research, the global tubeless insulin pump market size will grow from USD 2.92 billion in 2025 to nearly USD 13.65 billion by 2034, with an expected CAGR of 18.74% from 2025 to ...

Shares of Insulet Corporation (PODD) slipped ~7% on Thursday as the insulin pump maker announced its long-term financial ...

Renu MedTech today unveiled InsuPatch, its tubeless insulin patch pump designed specifically for advancing diabetes care in ...

According to DataM Intelligence, the Insulin Delivery Devices Market Size reached USD 20.26 billion in 2024 and is projected ...

Insulet also expects in 2028 to release the Omnipod Fully Closed Loop for Type 2, which will automate insulin delivery for patients with type 2 diabetes. It said the out-of-the-box product will be the ...

Insulet Corporation ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company's global ...

Insulet stock yo-yoed Thursday despite broadly beating sales forecasts for its body-worn insulin pump, Omnipod.

Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s ...

Investing.com -- Insulet Corporation (NASDAQ:PODD) stock declined 6% amid broad equity market weakness, despite the company outlining an ambitious long-term growth strategy at its 2025 Investor Day.